Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Plasma from recovered patients recently received a controversial FDA emergency use authorization as a potential treatment for COVID-19.
Janssen has entered into a collaboration with Achillion to develop and commercialize hepatitis C treatments.
FDA has granted fast-track status to Galmed Pharmaceuticals’ aramchol, an investigatory treatment for non-alcoholic steatohepatitis (NASH).
The FDA has sped up the development and approval process for promising new hepatitis C therapies from three different companies.
ACH-3102, a hepatitis C drug under development by Achillion Pharmaceuticals, has received Fast Track status from the FDA, according to an...
The FDA has assigned the Fast Track designation to Achillion Pharmaceuticals, Inc.’s ACH-1625
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.